MCID: PTT006
MIFTS: 56

Pituitary Adenoma

Categories: Genetic diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Pituitary Adenoma

MalaCards integrated aliases for Pituitary Adenoma:

Name: Pituitary Adenoma 54 12 29 52 14 69
Pituitary Neoplasms 42 69
Adenoma of the Pituitary Gland 12

Characteristics:

OMIM:

54
Miscellaneous:
incomplete penetrance
adult onset
adenomas may be functioning or nonfunctioning

Inheritance:
autosomal dominant


Classifications:



External Ids:

OMIM 54 617540
Disease Ontology 12 DOID:3829
MeSH 42 D010911
NCIt 47 C3329
UMLS 69 C0032000

Summaries for Pituitary Adenoma

OMIM : 54
Both familial and sporadic pituitary adenomas have been found to be caused by germline mutation in the CDH23 gene. Familial pituitary adenoma types include growth hormone (GH)-secreting and nonfunctional tumors. Sporadic pituitary adenoma types include GH-secreting, nonfunctional, prolactin (PRL)-secreting, adrenocorticotropin (ACTH)-secreting, thyroid-stimulating hormone (TSH)-secreting, and plurihormonal (GH and TSH) tumors. For a general description and a discussion of genetic heterogeneity of pituitary adenomas, see PITA1 (102200). (617540)

MalaCards based summary : Pituitary Adenoma, also known as pituitary neoplasms, is related to functioning pituitary adenoma and pituitary adenoma, prolactin-secreting. An important gene associated with Pituitary Adenoma is CDH23 (Cadherin Related 23), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and endothelial, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 72 Pituitary adenomas are tumors that occur in the pituitary gland. Pituitary adenomas are generally... more...

Related Diseases for Pituitary Adenoma

Diseases related to Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
id Related Disease Score Top Affiliating Genes
1 functioning pituitary adenoma 34.1 POMC SST
2 pituitary adenoma, prolactin-secreting 32.2 AIP CDH23 GH1 GNAS GPR101 IGF1
3 neuritis 30.3 SST SSTR2 SSTR5
4 hypertrichosis 29.6 IGF1 POMC SST
5 pheochromocytoma 29.0 CRH MEN1 POMC SST
6 pituitary adenoma, acth-secreting 28.9 AIP CDH23 GH1 GNAS IGF1 MEN1
7 familial isolated pituitary adenoma 12.3
8 pituitary adenoma, growth hormone-secreting 12.3
9 pituitary adenoma, growth hormone-secreting 2 12.2
10 aip-related familial isolated pituitary adenomas 12.1
11 non-functioning pituitary adenoma 12.0
12 silent pituitary adenoma 12.0
13 functionless pituitary adenoma 11.8
14 null pituitary adenoma 11.8
15 chromophobe adenoma 11.4
16 cushing's syndrome 11.2
17 pituicytoma 11.2
18 chiasmal syndrome 11.2
19 adenoma 11.2
20 tsh producing pituitary tumor 11.0
21 somatomammotropinoma 11.0
22 adrenal gland hyperfunction 10.9
23 paroxysmal hemicrania 10.9
24 acth-independent macronodular adrenal hyperplasia 10.9
25 chromosome xq26.3 duplication syndrome 10.9
26 hyperpituitarism 10.9
27 g6pc3 deficiency 10.8 GH1 PRL
28 extraskeletal ewing sarcoma 10.7 AIP MEN1
29 didymosis aplasticosebacea 10.7 AIP MEN1
30 simple cryoglobulinemia 10.6 GH1 SST
31 pityriasis rotunda 10.6 GH1 POU1F1 PRL
32 oral leukoedema 10.6 SST SSTR2
33 lymphoma, gastric non hodgkins type 10.6 GH1 POMC
34 vertebral artery occlusion 10.5 AIP POMC PRL
35 african histoplasmosis 10.5 POMC PRL SST
36 lymphoepithelioma-like carcinoma 10.5 POMC PRL SST
37 familial myelofibrosis 10.4 AIP CDH23
38 pemphigus foliaceus 10.4 MEN1 SST
39 prolactin producing pituitary tumor 10.4 IGF1 POMC SST
40 water-clear cell adenoma 10.4 PRL SST
41 immune system organ benign neoplasm 10.4 IGF1 POMC PRL
42 pandas 10.4 MEN1 SST
43 lipase deficiency, combined 10.4 GH1 IGF1
44 acromegaly 10.4
45 cowden syndrome 3 10.3 MEN1 SST SSTR2
46 pelvic muscle wasting 10.3 IGF1 POMC PRL
47 chondroma 10.3 IGF1 POMC SST
48 olfactory nerve neoplasm 10.3 GHRH POMC PRL
49 osteoclast-like giant cell neoplasm of the pancreas 10.3 GHRH POMC PRL
50 benign shuddering attacks 10.3 GNAS MEN1 SST

Graphical network of the top 20 diseases related to Pituitary Adenoma:



Diseases related to Pituitary Adenoma

Symptoms & Phenotypes for Pituitary Adenoma

Symptoms via clinical synopsis from OMIM:

54

Endocrine Features:
pituitary adenoma

Neurologic- Central Nervous System:
pituitary adenoma


Clinical features from OMIM:

617540

MGI Mouse Phenotypes related to Pituitary Adenoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.25 AIP CDH23 CRH GHRH GNAS IGF1
2 homeostasis/metabolism MP:0005376 10.24 PRL SST SSTR2 SSTR5 TRH AIP
3 endocrine/exocrine gland MP:0005379 10.21 AIP CRH GHRH GNAS IGF1 MEN1
4 immune system MP:0005387 10.02 POMC POU1F1 PRKAR1A PRL SST CRH
5 liver/biliary system MP:0005370 9.86 AIP CRH GHRH GNAS MEN1 POMC
6 nervous system MP:0003631 9.73 SST SSTR2 TRH CDH23 CRH GHRH
7 neoplasm MP:0002006 9.7 AIP GNAS IGF1 MEN1 POMC PRKAR1A
8 reproductive system MP:0005389 9.23 CDH23 GHRH IGF1 MEN1 POU1F1 PRKAR1A

Drugs & Therapeutics for Pituitary Adenoma

Drugs for Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-23-7 5754 657311
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Menthol Approved Phase 4 2216-51-5 16666
4
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2 83150-76-9 383414 6400441
5
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
6
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
7
Somatostatin Approved Phase 4,Phase 2,Phase 3 38916-34-6, 51110-01-1 53481605
8 lanreotide Approved Phase 4 108736-35-2
9
Cefazolin Approved Phase 4 25953-19-9 656510 33255
10
Cefdinir Approved Phase 4 91832-40-5 6915944
11
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
12
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
13
Sulfamethoxazole Approved Phase 4 723-46-6 5329
14
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
15
Liraglutide Approved Phase 4 204656-20-2 44147092
16
Metformin Approved Phase 4 657-24-9 14219 4091
17
Zinc Approved Phase 4 7440-66-6 32051 23994
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
20
Butyric Acid Experimental Phase 4 107-92-6 264
21
Lactitol Investigational Phase 4 585-86-4 3871
22 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 2
24 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
25 Cortisol succinate Phase 4,Phase 3,Phase 2
26 glucocorticoids Phase 4,Phase 2,Phase 3
27 Hormone Antagonists Phase 4,Phase 2,Phase 3,Early Phase 1
28 Hormones Phase 4,Phase 2,Phase 3,Early Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Early Phase 1
30 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 3,Phase 2
31 Hydrocortisone acetate Phase 4,Phase 3,Phase 2
32 Hydrocortisone-17-butyrate Phase 4
33 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
34 insulin Phase 4,Phase 2
35 Insulin, Globin Zinc Phase 4,Phase 2
36 Antiparkinson Agents Phase 4,Phase 3,Phase 2
37 Dopamine Agents Phase 4,Phase 3,Phase 2
38 Dopamine agonists Phase 4,Phase 3,Phase 2
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Bacterial Agents Phase 4
41 Antibiotics, Antitubercular Phase 4
42 HIV Protease Inhibitors Phase 4
43
protease inhibitors Phase 4
44 Angiopeptin Phase 4
45 Anti-Infective Agents Phase 4,Phase 2
46 Antimalarials Phase 4
47 Antiparasitic Agents Phase 4
48 Antiprotozoal Agents Phase 4
49 Antitubercular Agents Phase 4
50 cefuroxime axetil Phase 4

Interventional clinical trials:

(show top 50) (show all 95)

id Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
3 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
4 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
5 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
6 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
7 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
8 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
9 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
10 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
11 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
12 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
13 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
14 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
15 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
16 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous formulation
17 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 SOM230 LAR 30 mg;SOM230 LAR 10 mg
18 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
19 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
20 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
21 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
22 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
23 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699
24 Dynamic Hormone Diagnostics in Endocrine Disease Not yet recruiting NCT02934399 Phase 2, Phase 3
25 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
26 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
27 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
28 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
29 An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly Completed NCT00171730 Phase 2 Pasireotide
30 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
31 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
32 Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Recruiting NCT01283542 Phase 2 Pasireotide LAR
33 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
34 Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy Recruiting NCT01849484 Phase 2
35 Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas Recruiting NCT01444209 Phase 2
36 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
37 Treatment of Cushing's Disease With R-roscovitine Recruiting NCT02160730 Phase 2 R-roscovitine
38 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
39 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
40 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
41 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
42 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
43 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2 Pasireotide
44 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
45 Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas Terminated NCT00929669 Phase 2 pasireotide LAR
46 Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Withdrawn NCT01203618 Phase 2 Farletuzumab
47 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Recruiting NCT02769533 Phase 1 OTL0038;Benadryl
48 Intraoperative Imaging of Pituitary Adenomas by OTL Active, not recruiting NCT02629549 Phase 1 OTL38
49 Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects Unknown status NCT02574793
50 The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor Unknown status NCT01377701

Search NIH Clinical Center for Pituitary Adenoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: pituitary neoplasms

Genetic Tests for Pituitary Adenoma

Genetic tests related to Pituitary Adenoma:

id Genetic test Affiliating Genes
1 Pituitary Adenoma 29

Anatomical Context for Pituitary Adenoma

MalaCards organs/tissues related to Pituitary Adenoma:

39
Pituitary, Thyroid, Endothelial, Brain, Liver, Testes, Bone

Publications for Pituitary Adenoma

Articles related to Pituitary Adenoma:

(show top 50) (show all 1623)
id Title Authors Year
1
Thyrotropin-producing pituitary adenoma simultaneously existing with Graves' disease: a case report. ( 28061802 )
2017
2
Pituitary adenoma with adipose tissue: A new metaplastic variant. ( 28070930 )
2017
3
A Case of Pituitary Carcinoma Initially Diagnosed as an Ectopic Growth Hormone Producing Pituitary Adenoma with a High Ki-67 Labeling Index. ( 28586933 )
2017
4
Incidence of malignant tumours in patients with a non-functioning pituitary adenoma. ( 28274953 )
2017
5
Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing's disease. ( 28420444 )
2017
6
Multihormonal pituitary adenoma concomitant with Pit-1 and Tpit lineage cells causing acromegaly associated with subclinical Cushing's disease: a case report. ( 28865461 )
2017
7
Incidental pituitary adenoma detected by (18)F-FDG PET/CT and (18)F-choline PET/CT in the same patient. ( 28800881 )
2017
8
'Coexisting pituitary adenoma and suprasellar meningioma-a coincidence or causation effect: report of two cases and review of the literature'. ( 28560021 )
2017
9
Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma. ( 28709401 )
2017
10
T cell lymphoblastic lymphoma/leukemia within an adrenocorticotropic hormone and thyroid stimulating hormone positive pituitary adenoma: A cytohistological correlation emphasizing importance of intra-operative squash smear. ( 28295636 )
2017
11
Fatal Mycotic Aneurysm of the Basilar Artery Caused by Aspergillus fumigatus in a Patient with Pituitary Adenoma and Meningitis. ( 28770205 )
2017
12
RIZ1 and histone methylation status in pituitary adenomas. ( 28718376 )
2017
13
Simultaneous Occurrence of a Pituitary Adenoma and a Foramen Magnum Meningioma: Case Report. ( 27989978 )
2017
14
An intrasellar pituitary adenoma-gangliocytoma presenting as acromegaly. ( 28469929 )
2017
15
Seeding of a Pituitary Adenoma or Atypical Pituitary Carcinoma? ( 28589060 )
2017
16
Intraoperative Ultrasound in Patients Undergoing Transsphoidal Surgery for Pituitary Adenoma: Systematic Review. ( 28736351 )
2017
17
Transdifferentiation of Neuroendocrine Cells: Gangliocytoma Associated With Two Pituitary Adenomas of Different Lineage in MEN1. ( 28079577 )
2017
18
Endoscopic Endonasal Resection of a Mixed Lesion of Gangliocytoma and Nonfunctioning Pituitary Adenoma. ( 28532920 )
2017
19
Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma. ( 27227698 )
2017
20
Hypopituitarism after gamma knife radiosurgery for pituitary adenoma. ( 28537768 )
2017
21
Relationship between RSUME and HIF-1I+/VEGF-A with invasion of pituitary adenoma. ( 27989771 )
2017
22
Granulomatous hypophysitis caused by Rathke's cleft cyst mimicking a growth hormone-secreting pituitary adenoma. ( 28484553 )
2017
23
Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT. ( 28288092 )
2017
24
Decreased nitric oxide serum level after pituitary adenoma resection. ( 28945050 )
2017
25
Complex effects of apoplexy secondary to pituitary adenoma. ( 27802176 )
2017
26
Radiological Predictors for Extent of Resection in Pituitary Adenoma Surgery. A Single-center study. ( 28899832 )
2017
27
Amelanotic melanocytoma of the sella mimicking pituitary adenoma. ( 28853696 )
2017
28
A retrospective review of 34 cases of pediatric pituitary adenoma. ( 28721598 )
2017
29
Cryptococcal meningitis after transnasal transsphenoidal pituitary microsurgery of ACTH-secreting pituitary adenoma: A case report. ( 28700464 )
2017
30
Ovarian hyperstimulation syndrome due to follicle-stimulating hormone-secreting pituitary adenomas. ( 28676954 )
2017
31
Non-functioning pituitary adenoma underwent surgery: A multicenter retrospective study over the last four decades (1977-2015). ( 28389053 )
2017
32
Central hypogonadism due to a giant, "silent" FSH-secreting, atypical pituitary adenoma: effects of adenoma dissection and short-term Leydig cell stimulation by luteinizing hormone (LH) and human chorionic gonadotropin (hCG). ( 28067604 )
2017
33
Decreased TAp63 and I9Np63 mRNA Levels in Most Human Pituitary Adenomas Are Correlated with Notch3/Jagged1 Relative Expression. ( 28078618 )
2017
34
Nasal Lobular Capillary Hemangioma as a Complication after an Endoscopic Transsphenoidal Gonadotrophin-Producing Pituitary Adenoma Resection. ( 28326242 )
2017
35
Increased I^a89catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach. ( 28260015 )
2017
36
Successful management of octreotide-insensitive thyrotropin-secreting pituitary adenoma with bromocriptine and surgery: A case report and literature review. ( 28885368 )
2017
37
A Case of Coincidental Intrasellar Chordoma and Pituitary Adenoma. ( 28516081 )
2017
38
Efficacy of sellar opening in the pituitary adenoma resection of transsphenoidal surgery influences the degree of tumor resection. ( 28738798 )
2017
39
Treatment of a thyrotropin-secreting pituitary adenoma (TSH-oma) with pasireotide LAR. ( 28741655 )
2017
40
Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile. ( 28315020 )
2017
41
Germline Mutations in CDH23, Encoding Cadherin-Related 23, Are Associated with Both Familial and Sporadic Pituitary Adenomas. ( 28413019 )
2017
42
An FSH and TSH pituitary adenoma, presenting with precocious puberty and central hyperthyroidism. ( 28721217 )
2017
43
Pituitary Adenoma and Hyperprolactinemia Accompanied by Idiopathic Granulomatous Mastitis. ( 28321344 )
2017
44
Does MMP-9 Gene Polymorphism Play a Role in Pituitary Adenoma Development? ( 28194042 )
2017
45
Thyrotropic pituitary adenoma with plurihormonal immunoreactivity. ( 28879926 )
2017
46
Intratumoral granulomatous reaction in recurrent pituitary adenoma: A unique presentation. ( 28862230 )
2017
47
Folate receptor overexpression can be visualized in real time during pituitary adenoma endoscopic transsphenoidal surgery with near-infrared imaging. ( 28841122 )
2017
48
A COMPARISON OF PATIENT AND HEALTH-CARE PROFESSIONAL VIEWS WHEN ASSESSING QUALITY OF INFORMATION ON PITUITARY ADENOMA AVAILABLE ON THE INTERNET. ( 28816540 )
2017
49
Cerebrospinal fluid rhinorrhoea following transsphenoidal surgery for pituitary adenoma: experience in a Chinese centre. ( 28872159 )
2017
50
Mixed Gangliocytoma-Pituitary Adenoma: Insights on the Pathogenesis of a Rare Sellar Tumor. ( 28079576 )
2017

Variations for Pituitary Adenoma

ClinVar genetic disease variations for Pituitary Adenoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CDH23 NM_022124.5(CDH23): c.4136G> T (p.Arg1379Leu) single nucleotide variant Pathogenic rs767004225 GRCh38 Chromosome 10, 71734271: 71734271
2 CDH23 NM_022124.5(CDH23): c.9412C> T (p.Arg3138Trp) single nucleotide variant Pathogenic rs1052484950 GRCh37 Chromosome 10, 73572268: 73572268
3 CDH23 NM_022124.5(CDH23): c.9886G> A (p.Asp3296Asn) single nucleotide variant risk factor rs372388344 GRCh37 Chromosome 10, 73574856: 73574856

Cosmic variations for Pituitary Adenoma:

9 (show all 11)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM771 PIK3CA pituitary,NS,adenoma,PRL c.3073A>G p.T1025A 12
2 COSM760 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 12
3 COSM22623 MEN1 pituitary,NS,adenoma,TSH c.1050-2A>G p.? 12
4 COSM483 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 12
5 COSM482 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 12
6 COSM27887 GNAS pituitary,NS,adenoma,GH c.601C>T p.R201C 12
7 COSM27896 GNAS pituitary,NS,adenoma,GH c.680A>G p.Q227R 12
8 COSM27888 GNAS pituitary,NS,adenoma,GH c.680A>T p.Q227L 12
9 COSM27895 GNAS pituitary,NS,adenoma,GH c.602G>A p.R201H 12
10 COSM27899 GNAS pituitary,NS,adenoma,GH c.601C>A p.R201S 12
11 COSM493 HRAS pituitary,NS,carcinoma,ACTH c.52G>A p.A18T 8

Copy number variations for Pituitary Adenoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 55796 11 55700000 65900000 Copy number Pituitary adenoma
2 58390 11 67250504 67258578 Amplification AIP Pituitary adenoma
3 64485 12 12870301 12875305 Amplification CDKN1B Pituitary adenoma

Expression for Pituitary Adenoma

Search GEO for disease gene expression data for Pituitary Adenoma.

Pathways for Pituitary Adenoma

Pathways related to Pituitary Adenoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 CRH GHRH GNAS IGF1 MEN1 POMC
2
Show member pathways
12.63 CRH GH1 GHRH GNAS POMC PRL
3
Show member pathways
12.5 CRH GH1 GHRH GNAS POMC PRKAR1A
4
Show member pathways
11.88 GH1 IGF1 POMC TSHB
5 11.62 CRH GNAS POMC
6 11.52 POMC POU1F1 PRL
7 11.52 CRH GHRH GNAS POMC TSHB
8 11.32 CRH GNAS IGF1
9 11.24 GH1 GHRH GNAS IGF1 PRKAR1A
10 10.25 CRH POMC

GO Terms for Pituitary Adenoma

Cellular components related to Pituitary Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 CRH GH1 GHRH GNAS IGF1 POMC
2 endosome lumen GO:0031904 8.96 GH1 PRL

Biological processes related to Pituitary Adenoma according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.8 MEN1 POU1F1 SST SSTR2 SSTR5
2 female pregnancy GO:0007565 9.63 CRH GNAS PRL
3 positive regulation of JAK-STAT cascade GO:0046427 9.55 GH1 PRL
4 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.54 GNAS GPR101
5 response to corticosterone GO:0051412 9.49 CRH TRH
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.48 GH1 PRL
7 adenohypophysis development GO:0021984 9.43 GHRH POU1F1
8 positive regulation of cAMP biosynthetic process GO:0030819 9.43 CRH GHRH GNAS
9 hormone-mediated apoptotic signaling pathway GO:0008628 9.37 CRH SST
10 positive regulation of multicellular organism growth GO:0040018 9.33 GH1 GHRH POU1F1
11 somatostatin signaling pathway GO:0038170 9.32 SSTR2 SSTR5
12 cell-cell signaling GO:0007267 9.17 GHRH GPR101 POMC SST SSTR2 TRH
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.13 GH1 GHRH IGF1
14 signal transduction GO:0007165 10.11 CRH GNAS GPR101 IGF1 POMC SSTR2
15 G-protein coupled receptor signaling pathway GO:0007186 10 GNAS GPR101 SST SSTR2 SSTR5 TSHB

Molecular functions related to Pituitary Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide binding GO:0042923 9.37 SSTR2 SSTR5
2 insulin-like growth factor receptor binding GO:0005159 9.32 GNAS IGF1
3 somatostatin receptor activity GO:0004994 9.26 SSTR2 SSTR5
4 hormone activity GO:0005179 9.23 CRH GH1 IGF1 POMC PRL SST
5 corticotropin-releasing hormone receptor 1 binding GO:0051430 9.16 CRH GNAS
6 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....